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ORIGINAL RESEARCH
Drug- Eluting or Bare- Metal Stents for Left 
Anterior Descending or Left Main Coronary 
Artery Revascularization
Raffaele Piccolo, MD, PhD; Kaare H. Bonaa, MD, PhD; Orestis Efthimiou , PhD; Olivier Varenne , MD, PhD; 
Philip Urban, MD; Christoph Kaiser, MD; Lorenz Räber , MD, PhD; Adam de Belder, MD; Wouter Remkes, MD;  
Arnoud W. J. van’t Hof, MD, PhD; Goran Stankovic , MD, PhD; Pedro A. Lemos , MD, PhD;  
Tom Wilsgaard, MSc, PhD; Jörg Reifart , MD; Alfredo E. Rodriguez, MD, PhD; Expedito E. Ribeiro, MD;  
Patrick W. J. C. Serruys , MD, PhD; Alex Abizaid, MD; Manel Sabaté , MD, PhD; Robert A. Byrne , MD, PhD;  
Jose M. de la Torre Hernandez , MD, PhD; William Wijns , MD, PhD; Giovanni Esposito , MD, PhD;  
Peter Jüni , MD, PhD; Stephan Windecker , MD; Marco Valgimigli , MD, PhD; the Coronary Stent Trialists’ 
(CST) Collaboration
BACKGROUND: New- generation drug- eluting stents (DES) reduce target- vessel revascularization compared with bare- metal 
stents (BMS), and recent data suggest that DES have the potential to decrease the risk of myocardial infarction and cardiovas-
cular mortality. We evaluated the treatment effect of DES versus BMS according to the target artery (left anterior descending 
[LAD] and/or left main [LM] versus other territories [no- LAD/LM]).
METHODS AND RESULTS: The Coronary Stent Trialist (CST) Collaboration gathered individual patient data of randomized trials 
of DES versus BMS for the treatment of coronary artery disease. The primary outcome was the composite of cardiac death 
or myocardial infarction. Hazard ratios (HRs) with 95% CIs were derived from a 1- stage individual patient data meta- analysis. 
We included 26 024 patients across 19 trials: 13 650 (52.4%) in the LAD/LM and 12 373 (47.6%) in the no- LAD/LM group. At 
6- year follow- up, there was strong evidence that the treatment effect of DES versus BMS depended on the target vessel (P- 
interaction=0.024). Compared with BMS, DES reduced the risk of cardiac death or myocardial infarction to a greater extent in 
the LAD/LM (HR, 0.76; 95% CI, 0.68– 0.85) than in the no- LAD/LM territories (HR, 0.93; 95% CI, 0.83– 1.05). This benefit was 
driven by a lower risk of cardiac death (HR, 0.83; 95% CI, 0.70– 0.98) and myocardial infarction (HR, 0.74; 95% CI, 0.65– 0.85) 
in patients with LAD/LM disease randomized to DES. An interaction (P=0.004) was also found for all- cause mortality with 
patients with LAD/LM disease deriving benefit from DES (HR, 0.86; 95% CI, 0.76– 0.97).
CONCLUSIONS: As compared with BMS, new- generation DES were associated with sustained reduction in the composite of 
cardiac death or myocardial infarction if used for the treatment of LAD or left main coronary stenoses.
REGISTRATION: URL: https://www.crd.york.ac.uk/PROSPERO; Unique identifier: CRD42017060520.
Key Words: bare- metal stents ■ drug- eluting stent ■ left anterior descending artery ■ left main disease ■ percutaneous coronary 
intervention
Myocardial revascularization by means of per-cutaneous coronary intervention (PCI) has a central role in the management of patients with coronary artery disease.
1 Among patients undergoing 
PCI, lumen narrowing at the left anterior descending 
(LAD) coronary artery is reported to be as frequent as 
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40%, rendering the LAD artery the most common tar-
get vessel requiring coronary stenting. While left main 
(LM) coronary stenoses were traditionally regarded as 
an indication for surgical revascularization, more recent 
studies using first- or newer- generation drug- eluting 
stents (DES) showed similar outcomes on hard end 
points compared with coronary artery bypass grafting 
in patients with mild to moderate complexity/extension 
of coronary artery disease.2,3
The extent of myocardium subtended to the LAD, 
and even more for LM systems, amounts to as much 
as 50% to 60% of the left ventricle and, as a result, 
significant LAD/LM disease is associated with im-
paired prognosis compared with coronary disease 
in other territories.4,5 Contemporary, new- generation 
DES are recommended over bare- metal stents (BMS) 
in patients undergoing PCI for all lesions and patient 
subsets.6 In an individual patient data (IDP) analysis in-
cluding all available randomized trials, we found that 
new- generation DES reduced the risk of cardiac death 
or myocardial infarction (MI) compared with BMS 
mainly if used to treated the LAD territory.7 In the pres-
ent analysis, we leveraged the data from the Coronary 
Stent Trialists (CST) Collaboration to thoroughly inves-
tigate the efficacy and safety of new- generation DES in 
patients undergoing PCI in the LAD and/or LM artery 
compared with other territories.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request.
Study Design and Patient Population
Methodological aspects of the present individual pa-
tient data (IPD) analysis were reported elsewhere,7 
and the study was registered online in the PROSPERO 
(International Prospective Register of Systematic 
Reviews; http://www.crd.york.ac.uk/PROSP ERO/
displ ay_record.php?ID=CRD42 01706 0520). Briefly, 
the CST Collaboration includes all randomized clini-
cal trials comparing new- generation DES versus BMS 
in patients undergoing PCI. The search algorithm of 
the study is provided in Data S1. All principal investi-
gators provided IPD using an anonymized electronic 
data set (Data S1). Data were checked for complete-
ness and consistency, and were compared with the 
results of original publications. New- generation DES 
were identified as any DES subsequent to the Cypher 
sirolimus- eluting stent (Cordis, Miami Lakes, FL) and 
the Taxus paclitaxel- eluting stent (Boston Scientific, 
Natick, MA).
The present study was designed to evaluate the 
outcomes associated with DES versus BMS among 
patients undergoing PCI in the LAD/LM arteries com-
pared with the target vessels. For the purpose of this 
analysis, we excluded patients with missing informa-
tion on the intervened vessel as well as studies con-
tributing only to 1 group (LAD/LM versus non- LAD/LM) 
aiming to compare the risks of events within each trial 
and minimize the risk of heterogeneity across studies 
influencing the results (ecological bias).
All trials complied with the provisions of the 
Declaration of Helsinki, and the ethics committees at 
each study center approved the study protocols. All 
patients provided written informed consent for partici-
pation in the individual studies.
Outcomes
The prespecified primary outcome in this analysis was 
the time to first occurrence of composite of cardiac 
death or MI. Secondary outcomes included the time to 
first occurrence of all- cause death, cardiac death, MI, 
target- vessel revascularization (TVR), and definite stent 
thrombosis. Outcomes were analyzed at the longest 
available follow- up in the primary analysis, as well as 
at 5- and 1- year follow- up and with a 30- day and 1- 
year landmark. End point definitions in each trial are 
reported in Data S1.
CLINICAL PERSPECTIVE
What Is New?
• Patients undergoing percutaneous coronary in-
tervention in the territory of the left main or left 
anterior descending artery are at increased risk 
of cardiac death or myocardial infarction.
What Are the Clinical Implications?
• In about 26 000 patients randomized to new- 
generation drug- eluting stents or bare- metal 
stents, randomization to drug- eluting stents 
was associated with a stronger reduction in the 
risk of cardiac death or myocardial infarction 
when stents were implanted in the territory of 
the left main or left anterior descending artery 
compared with other territories.
Nonstandard Abbreviations and Acronyms
BMS bare- metal stent
DES drug- eluting stent
IPD individual patient data
LM left main
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Statistical Analysis
Continuous variables were summarized by their means 
and SD across all included patients. Categorical vari-
ables were summarized by the corresponding counts 
and percentages.
The risk of adverse events among patients under-
going PCI in the LAD/LM versus no- LAD/LM was eval-
uated by using a multivariable Cox regression model 
adjusted for clinically relevant variables, including age, 
sex, smoking, hypertension, hyperlipidemia, diabetes, 
previous MI, previous PCI, previous coronary artery by-
pass grafting, clinical presentation, and multivessel dis-
ease. All outcomes were analyzed using time- to- event 
analysis and according to the intention- to- treat princi-
ple (ie, patients were analyzed according to the allo-
cated treatment to DES or BMS). We first summarized 
the data using unadjusted Kaplan- Meier estimates at 
the longest available follow- up. We then performed 
a series of IPD meta- analyses. For all analyses, the 
pooled risk estimates were expressed as hazard ratios 
(HRs) with 95% CIs. We used a 1- stage fixed- effect 
model by using Cox regression analyses stratified by 
trial with robust estimator of variance.7 Heterogeneity 
was calculated with the I2 statistics from a 2- stage 
meta- analysis. As a guide, I2 values <25% indicated 
low, 25% to 50% indicated moderate, and >50% indi-
cated high heterogeneity. Two landmark analyses were 
performed: (1) an analysis with 1 landmark time point, 
calculating HRs between 0 and 365 days versus HRs 
>365 days; and (2) an analysis with 2 landmark time 
points, calculating HRs between 0 and 30 days versus 
HRs between 31 and 365 days versus HRs >365 days. 
As sensitivity analysis, we evaluated the treatment ef-
fect of DES versus BMS in LAD and LM groups, sepa-
rately, as well as in patients receiving a new- generation 
DES (ie, after the exclusion of early- generation DES). 
Finally, we performed a 2- stage meta- analysis using 
the DerSimonian- Laird random- effects model.
All P values we calculated were based on 2- sided 
tests. We used Stata Statistical Software, release 14 
(StataCorp LP, College Station, TX).
RESULTS
From the initial 26 616 participants, we excluded 408 
patients from one trial because PCI was exclusively 
performed in saphenous vein grafts8 and 185 patients 
across 12 trials because of missing information on the 
target vessel. Therefore, the final population consists 
of 26 023 patients enrolled across 19 trials, of whom 
13  650 (52.4%) belonged to the LAD/LM group and 
12 373 (47.6%) to the no- LAD/LM group.9– 27 In the LAD/
LM group, 12 037 (46.3%) patients received stenting in 
the LAD, 1369 (5.3%) patients underwent stenting in 
the LM and 244 (0.9%) in both coronary territories. Data 
S1 describes study characteristics, patient popula-
tions, and the definitions used for outcomes (Tables S1 
through S3). In the LAD/LM group, 7346 (53.8%) were 
randomized to DES and 6304 (46.2%) were rand-
omized to BMS; in the no- LAD/LM group, 6521 (52.7%) 
were randomized to DES and 5852 (47.3%) were rand-
omized to BMS. Baseline clinical characteristics were 
largely balanced between the 2 study groups (Table 1). 
Mean age between groups varied between 64.9 and 
66.6  years. About 74% of patients were men, and 
about 19% had diabetes. Approximately 50% of pa-
tients had MI with or without ST- segment elevation at 
the time of the index PCI. Types of implanted devices 
are listed in Table S4. In both groups, patients rand-
omized to BMS tended to receive stents with larger 
diameters and shorter lengths. The majority of patients 
received thin- strut stents (<100 μm); yet DES- treated 
patients more frequently received thick- strut stents 
(≥100 μm) as compared with those allocated to BMS 
irrespective of lesion location. Duration of dual anti-
platelet therapy was longer (on average 45– 55 days) in 
patients randomized to DES in both LAD/LM and no- 
LAD/LM groups. The mean (±SD) follow- up time was 
3.1±1.8 years (median, 2.1; interquartile range, 1.9– 4.9). 
Table S5 provides details on the risk of bias assess-
ment. Overall, trials were judged at low risk of bias, al-
though blinding of patients and performing physicians 
was done only in 2 trials.
Outcomes in Patients Undergoing PCI on 
LAD/LM Versus No- LAD/LM Artery
As depicted in Figure 1 and Figure S1, the multivari-
able regression model showed that patients undergo-
ing PCI in the LAD/LM artery had a higher risk of the 
primary outcome of cardiac death or MI compared 
with those undergoing PCI in other vessels (16.11% 
versus 14.67%; adjusted HR, 1.18; 95% CI, 1.06– 1.32; 
P=0.003). This risk increase emerged at 1 year and 
remained significant throughout the follow- up period. 
The risks of cardiac death, MI, TVR, and definite stent 
thrombosis were all higher in patients undergoing PCI 
in the LAD/LM artery. However, there was no evidence 
of a difference between the LAD/LM versus the no- 
LAD/LM group in terms of all- cause mortality.
Treatment Effect of DES Versus BMS by 
Target- Vessel Location
There was evidence for interaction (P=0.024) between 
randomized treatment (DES versus BMS) and the in-
tervened artery (LAD/LM versus no- LAD/LM) with re-
spect to the primary outcome of cardiac death or MI 
(Figures 2, 3 Panels A- B). At longest follow- up, DES, as 
compared with BMS, were associated with a greater 
reduction in the risk of cardiac death or MI in the LAD/
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Table 1. Clinical and Procedural Characteristics Stratified by Type of Presentation and Randomization
Patients with LAD/LM (n=13 650) Patients without LAD/LM (n=12 373)
DES (n=7346) BMS (n=6304) DES (n=6521) BMS (n=5852)
Age, y n=7344, 66.1±12.5 n=6302, 66.6±12.7 n=6521, 64.9±11.9 n=5852, 65.5±12.0
Male, n (%) n=7346, 5481 (74.6) n=6304, 4633 (73.5) n=6521, 4897 (75.1) n=5852, 4317 (73.8)
Smokers, n (%) n=7154, 1939 (27.1) n=6098, 1703 (27.9) n=6298, 2315 (36.8) n=5664, 2078 (36.7)
Hypertension, n (%) n=7326, 4331 (59.1) n=6285, 3681 (58.6) n=6502, 3784 (58.2) n=5828, 3362 (57.7)
Hyperlipidemi, n (%)a n=7198, 4029 (56.0) n=6167, 3436 (55.7) n=6349, 3741 (58.9) n=5676, 3236 (57.0)
Diabetes, n (%) n=7332, 1401 (19.1) n=6295, 1159 (18.4) n=6512, 1265 (19.4) n=5844, 1055 (18.1)
Insulin- treated n=1383, 226 (16.3) n=1134, 191 (16.8) n=1231, 198 (16.1) n=1067, 151 (14.2)
Previous MI, n (%) n=7324, 968 (13.2) n=6289, 859 (13.7) n=6500, 1077 (16.6) n=5829, 954 (16.4)
Previous PCI, n (%) n=5328, 849 (15.9) n=4295, 738 (17.2) n=4420, 954 (21.6) n=3825, 867 (22.7)
Previous CABG, n (%) n=7339, 247 (3.4) n=6302, 221 (3.5) n=6519, 514 (7.9) n=5852, 446 (7.6)
Indication to PCI, n (%)
Stable CAD n=7257, 2165 (29.8) n=6235, 1857 (29.8) n=6469, 1794 (27.7) n=5786, 1586 (27.4)
Unstable angina n=7320, 1068 (14.6) n=6272, 995 (15.9) n=6491, 849 (13.1) n=5819, 782 (13.4)
Non– ST- elevation MI n=7277, 1858 (25.5) n=6260, 1601 (25.6) n=6495, 1566 (24.1) n=5812, 1485 (25.6)




n=6454, 1367 (21.2) n=5530, 1132 (20.5) n=5705, 1392 (24.4) n=5118, 1189 (23.2)
Multivessel disease n=7127, 3271 (45.9) n=6091, 2633 (43.2) n=6190, 2398 (38.7) n=5517, 2003 (36.3)
Number of implanted 
stents
n=7341, 1.7±1.1 n=6295, 1.7±1.1 n=6512, 1.5±0.9 n=5842, 1.5±0.8
Total stent length, mm n=7310, 29.8±21.5 n=6259, 27.7±19.3 n=6468, 26.9±17.1 n=5802, 25.9±16.8
Mean stent diameter, 
mm
n=7311, 3.2±0.5 n=6257, 3.2±0.5 n=6467, 3.3±0.6 n=5801, 3.3±0.7
Overlapping stent n=6982, 1284 (18.4) n=5963, 1109 (18.6) n=6238, 1090 (17.5) n=5542, 1010 (18.2)
Number of stented 
segments, n (%)
n=7345 n=6301 n=6518 n=5850
0 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.0)
1 4936 (67.2) 4271 (67.8) 5211 (79.9) 4661 (79.7)
2 1684 (22.9) 1432 (22.7) 1047 (16.1) 988 (16.9)
3 537 (7.3) 433 (6.9) 208 (3.2) 165 (2.8)
4 140 (1.9) 114 (1.8) 47 (0.7) 27 (0.5)
5 37 (0.5) 44 (0.7) 3 (0.0) 8 (0.1)
6 9 (0.1) 6 (0.1) 1 (0.0) 0 (0.0)
7 2 (0.0) 1 (0.0) 1 (0.0) 0 (0.0)
Target- vessel location, n (%)
Left main artery n=7346, 1022 (13.9) n=6304, 591 (9.4) n=6521, 0 (0.0) n=5852, 0 (0.0)
Left anterior 
descending artery
n=7346, 6476 (88.2) n=6304, 5805 (92.1) n=6521, 0 (0.0) n=5852, 0 (0.0)
Left circumflex artery n=7346, 1117 (15.2) n=6304, 907 (14.4) n=6521, 2930 (44.9) n=5852, 2526 (43.2)
Right coronary 
artery
n=7346, 1127 (15.3) n=6303, 897 (14.2) n=6521, 4133 (63.4) n=5852, 3777 (64.5)
Type of DES, n (%)
Everolimus- eluting 
stent
n=7335, 3925 (53.5) … n=6508, 3536 (54.4) …
Biolimus- eluting 
stent
n=7335, 1463 (20.0) … n=6508, 1178 (18.1) …
Zotarolimus- eluting 
stent
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no- LAD/LM territory (HR, 0.93; 95% CI, 0.83– 1.05; 
P=0.241). For the individual components of the primary 
outcome (Figures 2 and 3 Panels C- F), although inter-
action testing was not significant, DES were associated 
with a lower risk of cardiac death (HR, 0.83; 95% CI, 
0.70– 0.98; P=0.030; P- interaction=0.135) and MI (HR, 
0.74; 95% CI, 0.65– 0.85; P<0.001; P- interaction=0.077) 
in the LAD/LM group. Heterogeneity in the treatment 
effect of DES versus BMS was more evident at 1- year 
follow- up, resulting in a significant interaction for both 
cardiac death (HR, 0.72; 95% CI, 0.58– 0.88 in LAD/
LM versus HR, 1.09; 95% CI, 0.83– 1.42 in no- LAD/LM; 
P- interaction=0.022) and MI (HR, 0.55; 95% CI, 0.46– 
0.66 in LAD/LM versus HR, 0.74; 95% CI, 0.60– 0.91 in 
no- LAD/LM; P- interaction=0.041).
At maximum follow- up, we found also strong evidence 
for an interaction (P=0.004) with respect to all- cause 
mortality (Figures  2 and 4 Panels A- B), which was 
significantly reduced with DES among patients under-
going PCI in the LAD/LM artery (HR, 0.86; 95% CI, 
0.76– 0.97; P=0.013) but not among patients undergo-
ing PCI in other vessels (HR, 1.12; 95% CI, 0.98– 1.28; 
P=0.086). The interaction effect for all- cause mortality 
was stronger at 1- year follow- up (P- interaction=0.001) 
with a signal of benefit (HR, 0.77; 95% CI, 0.65– 0.91) 
and harm (HR, 1.24; 95% CI, 1.01– 1.53) with DES in-
stead of BMS in the LAD/LM versus no- LAD/LM arter-
ies, respectively.
As shown in Figures  2 and 4, a consistently 
beneficial effect of DES, as compared with BMS, 
with regard to target- vessel revascularization (P- 
interaction=0.329) was found in both LAD/LM (HR, 
0.53; 95% CI, 0.47– 0.59) and no- LAD/LM group (HR, 
0.56; 95% CI, 0.49– 0.64). The risk of definite stent 
thrombosis was also similarly reduced by DES (P- 
interaction=0.721) in the LAD/LM (HR, 0.61; 95% CI, 
0.44– 0.83) and no- LAD/LM artery (HR, 0.64; 95% CI, 
0.44– 0.93).
Landmark Analyses
In the landmark analyses (Table 2), analyzing the HRs 
from 0 to 365 days and from 365 days to the end of 
follow- up, we found that the heterogeneity by vessel 
location was mainly attributable to stronger effects of 
DES in the LAD/LM group within the first year after 
PCI. In a sensitivity analysis with 2 landmark points, 
the time window of greatest benefit from DES instead 
of BMS for the LAD/LM vessels was observed from 1 
to 12 months after PCI (Table S6).
Sensitivity Analysis and Heterogeneity
We did not find clinically relevant heterogeneity be-
tween trials in both study groups (Table S7). When ap-
praised separately (Figure  5), the treatment effect of 
DESs versus BMSs was homogenous for both LAD 
and LM subgroups. Results remained similar after 
excluding patients receiving early- generation DES 
(Table S8). A 2- stage meta- analysis yielded similar re-
sults to the 1- stage model (Figures S2 and S3).
Patients with LAD/LM (n=13 650) Patients without LAD/LM (n=12 373)
DES (n=7346) BMS (n=6304) DES (n=6521) BMS (n=5852)
Sirolimus- eluting 
stent
n=7335, 339 (4.6) … n=6508, 325 (5.0) …
Other n=7335, 394 (5.4) … n=6508, 305 (4.6) …
Type of polymer, n (%) n=7180 … n=6375 …
Permanent- polymer 
DES
5188 (72.3) … 4765 (74.7) …
Biodegradable- 
polymer DES
1305 (18.2) … 1076 (16.9) …
Polymer- free DES 687 (9.6) … 534 (8.4) …
Thin- strut stent 
(<100 μm), n (%)
n=7335, 5772 (78.7) n=6298, 5339 (84.8) n=6508, 5223 (80.3) n=5838, 4953 (84.8)
Type of P2Y12 receptor 
inhibitor, n (%)
n=6719 n=5750 n=5761 n=5247
None 0 (0.0) 2 (0.0) 1 (0.0) 1 (0.0)
Clopidogrel 5475 (81.5) 5060 (88.0) 5081 (88.2) 4804 (91.6)
Ticagrelor 53 (0.8) 32 (0.6) 36 (0.6) 30 (0.6)
Prasugrel 1191 (17.7) 656 (11.4) 643 (11.2) 412 (7.9)
Duration of DAPT, d n=6492, 290±185 n=5477, 235±181 n=5519, 292±177 n=4950, 248±173
BMS indicates bare- metal stent; CABG, coronary artery bypass grafting; CAD, coronary artery disease; DAPT, dual antiplatelet therapy; DES, drug- eluting 
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DISCUSSION
The main findings of this IPD analysis that included the 
totality of randomized trials comparing new- generation 
DES versus BMS are that (1) DES were associated with 
a greater reduction in the risk of the primary outcome of 
cardiac death or MI as compared with BMS, when PCI 
was performed in the LAD or LM artery in comparison 
with other vessels; (2) patients receiving DES instead 
of BMS in the LAD/LM territory had also a lower risk 
of all- cause mortality; (3) irrespective of the intervened 
artery, DES were safer and more effective than BMS by 
reducing the risk of MI, target- vessel revascularization, 
and definite stent thrombosis; and (4) among patients 
undergoing PCI in the LAD/LM, we found a consist-
ently beneficial effect of DES versus BMS for both LAD 
and LM subgroups with respect to primary and sec-
ondary outcomes.
Although new- generation DES have replaced BMS 
in contemporary practice, the evidence from individ-
ual randomized trials in supporting their use is essen-
tially based on a lower risk of repeat revascularization 
procedures and stent thrombosis or MI. This latter 
effect has been demonstrated only in a minority of 
studies.21,22 The CST Collaboration was developed to 
comprehensively evaluate the efficacy and safety of 
new- generation DES compared with BMS. By includ-
ing 26 616 patients in 20 randomized trials, we found 
Figure 1. Clinical outcomes in patients undergoing percutaneous coronary intervention in the LAD/LM vs no- LAD/LM 
territory.
Squares indicate the HR (black for the longest follow- up, white for 5- and 1- year follow- up) and bars indicate 95% CI. HR indicates hazard 
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Figure 2. Effect of drug- eluting stents (DES) vs bare- metal stents (BMS) in patients undergoing percutaneous 
coronary intervention in the LAD/LM vs no- LAD/LM territory.
Data are shown at maximum, 5- y, and 1- y follow- up. HR indicates hazard ratio; LAD, left anterior descending artery; 
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Figure 3. Kaplan- Meier curves for the primary outcome of cardiac death or myocardial infarction 
and its components in patients undergoing percutaneous coronary intervention in the LAD/LM vs 
no- LAD/LM territory and randomized to new- generation drug- eluting stents (red line) or bare- metal 
stents (blue line).
BMS indicates bare- metal stents; DES, drug- eluting stents; HR, hazard ratio; LAD, left anterior descending 
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Figure 4. Kaplan- Meier curves for the secondary outcomes in patients undergoing percutaneous 
coronary intervention in the LAD/LM vs no- LAD/LM territory and randomized to new- generation 
drug- eluting stents (red line) or bare- metal stents (blue line).
BMS indicates bare- metal stent; DES, drug- eluting stents; HR, hazard ratio; LAD, left anterior descending 
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a 26% relative reduction in the risk of cardiac death or 
MI in favor of DES because of a reduced risk of MI and 
to a lesser extent cardiac death.7 The present analysis 
extends earlier results showing that new- generation 
DES provide differential benefits among patients un-
dergoing PCI of coronary segments with a larger area 
at risk, such as the LAD or LM arteries. We found 
that LAD- and/or LM- treated patients experienced a 
24% relative reduction in the hazard of cardiac death 
or MI at maximum follow- up when treated with DES, 
whereas a nonsignificant 7% relative risk reduction was 
observed in the no- LAD/LM group. At 1- year follow- up, 
the relative reduction in the risk of cardiac death or 
MI attested to 38% and 15% in the LAD/LM and no- 
LAD/LM groups, respectively. The superiority of new- 
generation DES over BMS for LAD/LM was driven by 
a decreased risk of both cardiac death (17% relative 
reduction) and MI (26% relative reduction). Conversely, 
only the MI component of the primary composite out-
come was borderline reduced by 12% in the no- LAD/
LM group at the time of longest follow- up. All- cause 
mortality was also reduced among patients in the LAD/
LM group but not in the no- LAD/LM group, in whom 
all- cause mortality was apparently higher with DES (HR 
at 1- year follow- up, 1.24; P=0.037). We do not have a 
mechanistically plausible explanation for this finding, 
which might simply be a chance finding.
Cardiac fatalities and MIs were robustly decreased 
by DES allocation solely in LAD/LM recipients, even 
though the magnitude of treatment response associ-
ated with DESs versus BMSs was comparable for both 
LAD/LM and no- LAD/LM groups in terms of efficacy 
(HRs for TVR, 0.53 versus 0.56) and safety outcomes 
(HRs for stent thrombosis, 0.61 versus 0.64). This might 
be explained by more prognostically relevant implica-
tions of stent- related failures in LAD or LM arteries in 
view of larger myocardium at risk. Patients in the LAD/
LM group had also a higher risk of all study outcomes, 
excepting all- cause death, suggesting a greater isch-
emic burden and thus benefit from safer and more ef-
fective coronary devices. In keeping with this, untreated 
LM stenosis as well as incomplete revascularization in-
volving the LAD, especially in its proximal segment, are 
conditions associated with a higher risk of mortality.28,29
Serial assessments of outcomes at 1- year, 5- year, 
and longest follow- up as well as landmark analyses 
allowed for the evaluation of interactions between 
device type and lesion location over time. In line with 
prior findings,7 we saw that the beneficial effects 
of DES on efficacy and safety end points accrued 
principally within the first year after PCI, even within 
30 days, with no further incremental benefit or loss 
thereafter. Consistently, there was a stronger evi-
dence of a difference between LAD/LM and no- LAD/
Figure 5. Effect of drug- eluting stents (DES) vs bare- metal stents (BMS) in patients undergoing 
percutaneous coronary intervention in the LAD vs LM artery.
HR indicates hazard ratio; LAD, left anterior descending artery; LM, left main artery; MI, myocardial 
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LM groups at 1- year follow- up with the heterogeneity 
in treatment response among the 2 groups reaching 
the strongest effect at 1 year. This again suggests 
that the observation of a larger benefit in the LAD/LM 
group with DES instead of BMS could be explained by 
the potentially more detrimental sequelae of TVR and 
stent thrombosis in these coronary tree segments, 
notwithstanding the comparable treatment effect of 
device type in LAD/LM and no- LAD/LM groups with 
respect to both TVR and stent thrombosis.
Limitations
Our study has a number of caveats and limita-
tions. First, as an important limitation to the study, 
we did not collect lesion location in our IPD and 
therefore were unable to disentangle the treat-
ment effect between proximal versus nonproximal 
LAD. Second, the study has limitations inherent in 
patient- level, pooled analyses reflecting the short-
comings of the original studies. Third, a mixture 
of new- generation DESs was used in the experi-
mental arm, despite the fact that a limited number 
of DESs were implanted as previously described.7 
Fourth, although outcomes were assessed at the 
maximum follow- up of 6  years, the mean follow-
 up of the study was about 3  years. Whether dif-
ferences between DES and BMS exist in the late 
follow- up and, importantly, whether the benefit of 
DES in the LAD/LM segments in terms of mortality 
is eroded in the long- term remain unaddressed by 
this study. However, other trials comparing new- 
generation DES with BMS are unlikely. Finally, we 
did not adjust or account for postrandomization 
covariates, such as actual duration of dual anti-
platelet therapy, to avoid violating the principle of 
randomization.
In conclusion, our collaborative meta- analysis based 
on the totality of available randomized data showed 
that the use of new- generation DES rather than BMS 
in patients requiring PCI in the left anterior descending 
artery or in the left main system conferred additional 
benefits, with larger reductions in the risk of the com-
posite outcome of cardiac death or MI, attributable to 
a reduction of both cardiac death and MI within the first 
year after intervention, without trade- off between effi-
cacy and safety thereafter. The use of new- generation 
DES in the LAD artery and/or in the LM coronary artery 
was associated with a sustained decrease in the risk of 
all- cause mortality at long- term follow- up.
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IPD were provided for the following variables, where available: demographic data and risk factors (age, sex, 
smoking status, hypertension, dyslipidemia, diabetes, insulin-treated diabetes), history of coronary artery 
disease (previous myocardial infarction, previous PCI, previous coronary artery bypass grafting), clinical 
presentation at the time of the index procedure (chronic coronary syndrome, unstable angina, non-ST-segment 
elevation acute coronary syndrome, ST-segment elevation myocardial infarction), pharmacological therapy 
during the index procedure (glycoprotein IIb/IIIa receptor inhibitors), angiographic and procedural data (number 
of implanted stents, mean stent length, mean stent diameter, overlapping stent, multivessel disease, 
intervened coronary vessel [left main coronary artery, left anterior descending artery, left circumflex artery, 
right coronary artery]), clinical outcomes (all-cause death, cardiac death, myocardial infarction, target-vessel 
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DES and 1 
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No 
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BASKET PROVE: Basel Stent Kosten-Effektivitäts Trial Prospective Validation Examination, BES: 
biolimus-eluting stent, BMS: bare-metal stent, COMFORTABLE: Comparison of Biolimus Eluted From 
an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction, 
CORACTO: The Coracto™ Rapamycin-Eluting Stent in chronic coronary occlusions, DAPT: Dual Anti-
Platelet Therapy, DES: drug-eluting stent, EES: everolimus-eluting stent, ELISA-3: Early or late 
intervention in high-risk non-ST-elevation acute coronary syndromes, ENDEAVOR II: The Medtronic 
Endeavor Drug Eluting Coronary Stent System in Coronary Artery Lesions, EUCATAX: comparison of 
a paclitaxel eluting stent with biodegradable polymer and glycolix coating versus bare metal stent 
design, EXAMINATION: clinical evaluation of the Xience-V stent in Acute Myocardial INfArcTION, 
INSPIRON: comparison of a novel sirolimus-eluting stent with abluminal biodegradable polymer and 
thin-strut cobalt-chromium alloy, LEADERS FREE: A Randomized Clinical Evaluation of the 
BioFreedom™ Stent, MASTER: Safety and Efficacy of Ultimaster Drug-eluting Stent in STEMI Patients, 
NORSTENT: Norwegian Coronary Stent Trial, PAINT: PercutAneous INTervention with biodegradable-
polymer based paclitaxel-eluting or sirolimus-eluting versus bare stents for de novo coronary lesions, 
PRODIGY: Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia 
Study, SENIOR: The SYNERGY II Everolimus elutiNg stent In patients Older than 75 years undergoing 
coronary Revascularization associated with a short dual antiplatelet therapy, SPIRIT I: A randomized 
comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent, STEALTH: 
STent Eluting A9 BioLimus Trial in Humans, TLR: target-lesion revascularization, TVR: Target-vessel 
revascularization, XIMA: Xience or Vision Stents for the Management of Angina in the Elderly, ZES: 
zotarolimus-eluting stent, ZEUS: Zotarolimus-eluting Endeavor sprint stent in Uncertain DES 
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Table S2. Main inclusion and exclusion criteria in pooled randomized trials. 
 
 
Study Major inclusion criteria Major exclusion criteria 
SPIRIT I 
stable or unstable angina or silent 
ischaemia and a single primary de 
novo coronary lesion 3 mm in 
diameter, that could be covered 
by an 18 mm stent, with TIMI flow 
grade more than 0 
AMI, LVEF<30%, LMA stenosis, 
ostial or bifurcation lesions, 
moderate to heavy calcification, 
presence of thrombus 
STEALTH 
symptoms of angina or ischemia 
and a lesion ≤ 24 mm in native 
vessel ≥ 2.75 mm and ≤ 4.0 mm 
AMI/stroke/TIA within the prior 7 
days, LVEF<30%, LMA 
stenosis, bifurcation lesion, 
need for more than 2 stent, prior 
stenting of target lesion, 
presence of thrombus 
ENDEAVOUR II 
evidence of myocardial ischemia 
and a single, untreated lesion 
(>14 but ≤27mm) in native vessel 
(≥2.25 but ≤3.5mm) 
AMI, PCI within the prior 30 
days, LVEF<30%, S-Cr>2 
mg/dL, LMA, ostial or bifurcation 
lesion, severe calcification 
PAINT 
evidence of myocardial ischemia 
and a single, untreated 
lesion≤29mm in native vessel 
(≥2·5 but ≤3·5mm) 
AMI, PCI of the target vessel 
within the prior 6 months, 
LVEF<30%, S-Cr>2 mg/dL, 
LMA stenosis, ostial or 
bifurcation lesions, severe 
calcification, presence of 
thrombus 
BASKET PROVE 
chronic or acute coronary 
disease, native vessel>3 but ≤4 
mm 
Cardiogenic shock, restenosis 
or thrombosis of prior stent, 
LMA or bypass graft lesion, 
need of oral anticoagulant, high 
risk of bleeding  
CORACTO CTO eligible to PCI 
High risk of bleeding, native 
vessel <2·5 or >4·5 mm 
EUCATAX 
evidence of myocardial ischemia 
and a de novo stenosis ≥70% in a 
major coronary vessel 
AMI, LVEF<30%, in-stent 
restenosis 
COMFORTABLE 
STEMI within 24 hours from 
symptom onset 
mechanical complication of AMI, 
need of oral anticoagulant, high 








STEMI within 48 hours from 
symptom onset and native vessel 
≥2·5 but ≤4mm 
need of oral anticoagulant, stent 
thrombosis 
PRODIGY 
Stable angina or acute coronary 
syndrome including STEMI with at 
least 1 lesion in native coronary 
vessel≥2·25 mm in diameter 
Planned surgery within 24 
months, history of bleeding, 
concomitant need of oral 
anticoagulant therapy 
INSPIRON 
evidence of myocardial ischemia 
and a de novo lesion <20mm in 
vessel≥2·25 but ≤3·5mm 
Cardiogenic shock, LVEF<30%, 
requiring of 3 stents, LMA, ostial 
or bifurcation lesion, presence of 
thrombus 
XIMA 
≥80 years old pts with stable 
angina or ACS and a lesion 
≥15mm long or <3mm wide 
STEMI, cardiogenic shock, 
history of gastrointestinal or 
intracerebral bleeding 
BASKET PROVE II 
chronic or acute coronary 
disease, native vessel>3 but ≤4 
mm 
Cardiogenic shock, restenosis 
or thrombosis of prior stent, 
LMA or bypass graft lesion, 
need of oral anticoagulant, high 
risk of bleeding  
LEADERS-FREE 
chronic or acute coronary disease 
and a high bleeding risk 
Cardiogenic shock, active 
bleeding, vessel <2·25 - 
>4·0mm 
ZEUS 
chronic or acute coronary disease 
and a high bleeding risk or high 
thrombosis risk or low restenosis 
risk 
Pregnancy 
ELISA-3 unstable angina or NSTEMI 
STEMI, cardiogenic shock, 
active bleeding, acute posterior 
infarction 
NORSTENT 
chronic or acute coronary disease 
and lesion of native vessel or 
bypass graft 
Prior PCI, bifurcation lesion, 
need of anticoagulant 
MASTER 
STEMI within 24 hours from 
symptom onset and a lesion of 
native vessel >2·5 but <4mm 
mechanical complication of AMI, 
need of oral anticoagulant, high 








chronic or acute coronary disease 
in patients aged 75 years or older 
Planned cardiac or non-cardiac 
surgery, history of haemorrhagic 
stroke, inability or 
contraindication to DAPT, life 
expectancy < 1year  
 
 
AMI: acute myocardial infarction, CTO: Chronic Total Occlusion, DAPT: Dual anti-platelet therapy, 
LMA: Left Main Artery, LVEF: Left Ventricle Ejection Fraction, NSTEMI: Non-ST-segment Elevation 
Myocardial Infarction, PCI: Percutaneous Coronary Intervention, S-Cr: Serum Creatinine, STEMI: ST-
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Table S3. Definition of clinical endpoints in randomized trials included in the IPD meta-analysis. 
 
 














All cardiac death 
cannot be clearly 
attributed to a 
vessel other than 
the target vessel 
All deaths that could not 
be unequivocally 
attributed to non-cardiac 
cause were considered 
cardiac deaths. 












in CK level 
to more than 
twice the 








Q waves in at least 
2 contiguous leads, 
or an elevation in 
CK levels to greater 
than twice the 
upper limit of 
normal in the 
presence of an 
elevated CK-MB 
level 
New Q waves or ST-
segment 
depression/elevation and 
rising of CK, CK-MB or 
cTn in the setting of 
clinical ischemia 
 a clinical event with 
typical 
electrocardiographic (Q 
waves or ST-segment 
elevation/depression) or 
enzymatic changes (cTn 
or CK-MB exceeding the 





typical chest pain combined 
with either new pathological 
Q waves or an increase in 
CK>3 the upper limit of 
normal, with a concomitant 














ischemia owing to 
stenosis>50%, or 
without signs of 
ischemia to 
stenosis>70% 
anywhere within the 
target vessel, 
revascularization for 
ischemia owing to 
stenosis>50%, or without 
signs of ischemia to 
stenosis>70% anywhere 





symptoms or signs of 
ischemia, or without signs of 
ischemia to stenosis>70% 
anywhere within the target 
vessel 
  
Endpdoint COMFORTABLE EXAMINATION PRODIGY INSPIRON XIMA BASKET PROVE II 
Cardiac death 




cardiac cause can be 
established. 
any death due to 
proximate cardiac 
cause, unwitnessed 












cause could be 
established. 
Not reported Nor reported 










Q waves with 
elevated biomarkers 
or chest pain; CK-
MB/cTn>1 ULN and 
chest pain or ECG 
changes 
Q waves with 
elevated 
biomarkers or chest 
pain; CK-MB/cTn>1 
ULN and chest pain 
or ECG changes 
Rise and/or fall 
of cardiac 
biomarker 
values with at 
least one value 
above the 99th 
percentile ULN 
with at least 
















and symptoms or 
ECG/imaging 
changes 
 a clinical event with typical 
electrocardiographic (Q 
waves or ST-segment 
elevation/depression) or 
enzymatic changes (cTn or 
CK-MB exceeding the 99th 





symptoms or signs of 
ischemia owing to 
stenosis>50%, or 
without signs of 
ischemia to 
stenosis>70% 
anywhere within the 
target vessel 
revascularization 
for symptoms or 
signs of ischemia 
owing to 
stenosis>50%, or 
without signs of 
ischemia to 
stenosis>70% 
anywhere within the 
target vessel 
Defined as 
repeat PCI or 
























any death in which a 
cardiac cause cannot 
be excluded, due to 
AMI, cardiac 
perforarion, arrhythmia, 
stroke within 30 days, 
procedural 
complication,  
Any death due to 
immediate cardiac cause, 
unwitnessed or unknown 
cause 
Not reported 
death within 28 days 
from onset 
symptoms of AMI, or 
UA, sudden death 
when there's no 
other clear reason.  
Not reported Not reported 
Myocardial infarction 
cTn or CK-MB>99th 
percentile ULN and 
symptoms or 
ECG/imaging changes 
cTn or CK-MB>99th 











cTn or CK-MB>99th 





myocardial necrosis in a 
clinical setting consistent 
with AMI according to 3rd 









PCI or surgery in the 
treated vessel with 
symptom and/or 
documented ischemia 
or for a stenosis > 70% 
revascularization for 
symptoms or signs of 
ischemia owing to 
stenosis>50%, or without 
signs of ischemia to 
stenosis>70% anywhere 
within the target vessel 
Not reported 
Clinically driven 
repeat PCI of the 
target vessel 




AMI: Acute myocardial infarction, CABG: coronary artery bypass grafting, CK: creatine kinase, CK-MB: creatine kinase myocardial band, cTn: cardiac Troponin, 
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Table S4. Type of implanted stents. 
 
 
Type of stent No. of patients   Percent Strut thickness (µm) 
          
Drug-eluting stents (n=13,867)       
  
Xience EES 4,005   28.9 81 
Promus EES 2,866   20.7 81 
Endeavor ZES 1,901   13.7 91 
Biofreedom BES 1,221   8.8 112 
Nobori BES 765   5.5 120 
Biomatrix BES 655   4.7 112 
Synergy EES 593   4.3 74 
Resolute ZES 475   3.4 91 
Ultimaster SES 368   2.7 80 
Eucatax PES 209   1.5 85 
Cypher SES 115   0.8 140 
Infinnium PES 111   0.8 60 
Supralimus SES 106   0.8 60 
Taxus PES 90   0.7 132 
Inspiron SES 41   0.3 75 
Coracto SE 34   0.3 80 
          
Bare-metal stents (n=12,156) 
        
Driver BMS 2,976   24.5 91 
Vision BMS 2,529   20.8 81 
Gazelle BMS 1,792   14.7 112 
Integrity BMS 914   7.5 91 
Liberté BMS 778   6.4 97 
Pro-kinetic BMS 760   6.3 60 
Omega/Rebel BMS 599   4.9 81 
Eucatech BMS 211   1.7 85 
Kaname BMS 120   1.0 81 
Multi-Link 8 BMS 92   0.8 81 
Chrono Carbostent BMS 81   0.7 80 
Milennium Matrix BMS 57   0.5 60 
Multi-Link Flexmaster BMS 56   0.5 81 
S-Stent 40   0.3 112 
Constant BMS 32   0.3 80 
Cronus BMS 20   0.2 75 
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Graftmaster BMS 2   0.02 520 
Multi-Link Zeta BMS 2   0.02 102 
           
 
Among patients randomized to new-generation DES, BMS were implanted in 22 (0.16%) patients and 
information was missing in 24 (0.17%) patients. Among patients randomized to BMS, DES were implanted in 
25 (0.2%) patients and information was missing in 812 (6.7%) patients. Mixed stents were used in 266 (1.9%) 
patients randomized to new-generation DES and 255 (2.0%) patients randomized to BMS. Early-generation 
DES were implanted in 205 (1.5%) patients randomized to DES. BMS: bare-metal stents. BES: Biolimus-
eluting stent. DES: drug-eluting stents. EES: Everolimus-eluting stent. PES: Paclitaxel-eluting stent. SES: 
Sirolimus-eluting stent. ZES: Zotarolimus-eluting stent. Abbott Vascular (Santa Clara, CA, USA) make Xience, 
Vision, Multi-link 8, Multi-Link Flexmaster, Multi-Link Zeta and Graftmaster. Alvimedica (Istanbul Turkey) make 
Constant, Coracto and Chrono Carbostent. AMG (Winsen, Germany) make AMG. B Braun (Melsungen, 
Germany) make Coroflex. Biosensors International (Jalan Tukang, Singapore) make BioMatrix, BioFredoom, 
Gazelle and S-Stent. Biotronik (Berlin, Germany) make Pro-kinetic. Boston Scientific (Marlborough, MA, USA) 
make Taxus, Promus and Liberté. Cordis (Eastbridgewater, NJ, USA) make Cypher. Eucatech (Reinhelfeden, 
Germany) make Eucatax and Eucatech. Medtronic (Minneapolis, MN, USA) make Endeavor, Resolute, Driver 
and Integrity. Sahajanand Medical Technologies (Surat, India) make Infinnium, Supralimus and Millenium 
Matrix. Scitech Medical (Goiàs, Brasil) make Inspiron and Cronus. Terumo (Tokyo, Japan) make Nobori, 
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SPIRIT I Low risk Low risk High-risk Low risk Low risk Low risk 
STEALTH Low risk Low risk Low risk Low risk Low risk Low risk 
ENDEAVOUR II Low risk Low risk Low risk Low risk Low risk Low risk 
PAINT Low risk Low risk High-risk Low risk Low risk Low risk 
BASKET PROVE Low risk Low risk High-risk Low risk Low risk Low risk 
CORACTO Unclear Unclear High-risk Low risk Low risk Low risk 
EUCATAX Low risk Low risk High-risk Low risk Low risk Low risk 
COMFORTABLE Low risk Low risk High-risk Low risk Low risk Low risk 
EXAMINATION Low risk Low risk High-risk Low risk Low risk Low risk 
PRODIGY Low risk Low risk High-risk Low risk Low risk Low risk 
INSPIRON Unclear Unclear High-risk Low risk Low risk Low risk 
XIMA Low risk Low risk High-risk Low risk Low risk Low risk 
BASKET PROVE II Low risk Low risk High-risk Low risk Low risk Low risk 
LEADERS-FREE Low risk Low risk Low risk Low risk Low risk Low risk 
ZEUS Low risk Low risk High-risk Low risk Low risk Low risk 
ELISA-3 Low risk Low risk Low-risk Low risk Low risk Low risk 
NORSTENT Low risk Low risk High-risk Low risk Low risk Low risk 
MASTER Low risk Low risk High-risk Low risk Low risk Low risk 













Table S6. Landmark analysis at 30-days and 1-year follow-up. 
 
  LAD/LM Patients (n=13,650)   Non-LAD/LM Patients (n=12,781) 
P-inter between subgroups   DES BMS   
HR (95%CI) P-value  
  DES BMS   
HR (95%CI) P-value  
  n=7346 n=6304     n=6622 n=6159   
                            
Cardiac death 
or MI 
          
                
0-30 days 264 (3.60) 285 (4.54)   0.76 (0.60-0.96) 0.021    177 (2.72) 172 (2.94)   0.87 (0.65-1.18) 0.382  0.539 
31-365 days 182 (2.61) 288 (4.86)   0.54 (0.45-0.64) <0.001    185 (2.97) 203 (3.62)   0.84 (0.69-1.03) 0.092  0.003 
>365 days 262 (9.14) 226 (9.42)   1.06 (0.89-1.27) 0.503    277 (9.04) 255 (9.44)   1.02 (0.86-1.22) 0.788  0.823 
All-cause 
death 
           
               
0-30 days 80 (1.09) 98 (1.56)   0.77 (0.56-1.06) 0.106    58 (0.89) 43 (0.74)   1.28 (0.84-1.97) 0.255  0.055 
31-365 days 175 (2.43) 198 (3.22)   0.77 (0.63-0.94) 0.012    170 (2.66) 129 (2.24)   1.23 (0.98-1.56) 0.079  0.004 
>365 days 258 (7.60) 251 (7.98)   0.96 (0.80-1.14) 0.620    271 (7.70) 250 (8.69)   1.04 (0.88-1.24) 0.644  0.533 
Cardiac death                           
0-30 days 69 (0.96) 85 (1.37)   0.79 (0.56-1.11) 0.177    47 (0.74) 40 (0.70)   1.10 (0.69-1.76) 0.675  0.248 
31-365 days 96 (1.36) 122 (2.02)   0.68 (0.52-0.88) 0.004    81 (1.30) 71 (1.26)   1.08 (0.78-1.49) 0.655  0.043 
>365 days 100 (2.73) 81 (2.73)   1.10 (0.82-1.47) 0.546    93 (2.52) 91 (3.48)   0.96 (0.72-1.29) 0.781  0.512 
Myocardial 
infarction 
           
               
0-30 days 212 (2.90) 228 (3.63)   0.72 (0.54-0.95) 0.022    145 (2.23) 145 (2.48)   0.81 (0.56-1.15) 0.236  0.700 
31-365 days 110 (1.58) 203 (3.43)   0.46 (0.37-0.58) <0.001    115 (1.85) 146 (2.61)   0.71 (0.55-0.91) 0.007  0.016 
>365 days 204 (7.78) 174 (8.01)   1.09 (0.89-1.34) 0.391    223 (7.70) 202 (8.02)   1.04 (0.86-1.26) 0.684  0.760 
TVR                           
0-30 days 70 (0.96) 90 (1.44)   0.75 (0.53-1.05) 0.092    46 (0.71) 72 (1.24)   0.53 (0.36-0.79) 0.002  0.187 
31-365 days 246 (3.47) 499 (8.28)   0.39 (0.34-0.46) <0.001    166 (2.63) 358 (6.32)   0.38 (0.32-0.46) <0.001  0.853 
>365 days 180 (5.17) 191 (7.11)   0.81 (0.66-0.99) 0.044    191 (6.38) 182 (6.42)   0.93 (0.76-1.14) 0.472  0.349 
Definite stent 
thrombosis 
           
               
0-30 days 39 (0.54) 54 (0.87)   0.63 (0.40-1.01) 0.053    15 (0.23) 33 (0.57)   0.33 (0.16-0.67) 0.002  0.114 
31-365 days 18 (0.25) 30 (0.50)   0.48 (0.27-0.87) 0.015    9 (0.14) 17 (0.30)   0.41 (0.19-0.88) 0.022  0.928 
>365 days 15 (0.37) 19 (0.68)   0.74 (0.38-1.43) 0.364     26 (0.81) 17 (0.53)   1.40 (0.76-2.59) 0.286  0.128 
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Heterogeneity is reported at maximum follow-up and was calculated with a two-stage meta-analysis. 
            
      I
2 Phet   
      
  
  
  LAD/LM (n=13,650)   
  
  
  Cardiac death or MI   0 0.651   
  All-cause death   6.9 0.376   
  Cardiac death   0 0.863   
  Myocardial infarction   8.4 0.358   
  Target-vessel revascularization   0 0.685   
  Definite stent thrombosis   0 0.572   
  No-LAD/LM (n=12,781)   
  
  
  Cardiac death or MI   26 0.162   
  All-cause death   28.2 0.141   
  Cardiac death   35.3 0.100   
  Myocardial infarction   18.6 0.246   
  Target-vessel revascularization   18.2 0.231   
  Definite stent thrombosis   0 0.888   
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Table S8. Sensitivity analysis after the exclusion of patients receiving early-generation DES. 
 
  LAD/LM Patients (N=13,550)   No-LAD/LM Patients (N=12,268)   
P-value for 
interaction   
DES BMS   
HR (95% CI) 
P-
value 
  DES BMS   




  N=7,246 N=6,304     N=6,416 N=5,852     
At longest FU                           
Cardiac death or MI 694 (14.35) 799 (17.73)   0.76 (0.68-0.85) <0.001   626 (14.24) 630 (15.30)   0.94 (0.83-1.05) 0.275   0.020 
All-cause death 500 (10.60) 547 (12.34)   0.84 (0.75-0.96) 0.007   494 (11.15) 422 (11.40)   1.13 (0.99-1.29) 0.069   0.002 
Cardiac death 261 (4.96) 288 (6.00)   0.82 (0.69-0.97) 0.024   221 (4.60) 202 (5.36)   1.04 (0.85-1.27) 0.699   0.105 
Myocardial infarction 513 (11.49) 605 (14.40)   0.74 (0.65-0.84) <0.001   470 (11.47) 493 (12.65)   0.89 (0.77-1.02) 0.101   0.068 
TVR 489 (9.30) 780 (16.03)   0.53 (0.47-0.59) <0.001   397 (9.60) 612 (13.42)   0.56 (0.49-0.64) <0.001   0.324 
Definite stent thrombosis 71 (1.14) 103 (2.04)   0.60 (0.44-0.83) 0.002   49 (1.20) 67 (1.39)   0.63 (0.43-0.93) 0.019   0.740 
At 5 years follow-up                           
Cardiac death or MI 685 (12.54) 784 (15.03)   0.76 (0.68-0.85) <0.001   610 (12.14) 619 (12.99)   0.92 (0.82-1.04) 0.204   0.034 
All-cause death 494 (9.57) 540 (11.43)   0.84 (0.74-0.95) 0.007   483 (9.89) 407 (9.22)   1.14 (1.00-1.31) 0.05   0.002 
Cardiac death 259 (4.72) 283 (5.29)   0.83 (0.70-0.98) 0.031   219 (4.38) 196 (4.25)   1.06 (0.87-1.30) 0.56   0.089 
Myocardial infarction 504 (9.62) 591 (11.71)   0.74 (0.65-0.85) <0.001   454 (9.30) 482 (10.27)   0.87 (0.76-1.01) 0.062   0.110 
TVR 486 (8.83) 773 (14.30)   0.53 (0.47-0.59) <0.001   385 (7.75) 607 (12.04)   0.55 (0.48-0.62) <0.001   0.490 
Definite stent thrombosis 71 (1.14) 102 (1.92)   0.61 (0.44-0.84) 0.002   47 (0.98) 66 (1.27)   0.61 (0.41-0.90) 0.013   0.863 
At 1 year follow-up                           
Cardiac death or MI 443 (6.17) 573 (9.17)   0.62 (0.54-0.72) <0.001   357 (5.63) 375 (6.46)   0.86 (0.73-1.02) 0.08   0.007 
All-cause death 254 (3.53) 296 (4.73)   0.77 (0.65-0.91) 0.003   225 (3.54) 172 (2.96)   1.24 (1.01-1.52) 0.044   0.001 
Cardiac death 164 (2.32) 207 (3.36)   0.71 (0.58-0.88) 0.002   128 (2.06) 111 (1.96)   1.09 (0.84-1.43) 0.514   0.020 
Myocardial infarction 319 (4.45) 431 (6.94)   0.56 (0.47-0.67) <0.001   255 (4.03) 291 (5.03)   0.75 (0.61-0.92) 0.006   0.041 
TVR 313 (4.42) 589 (9.60)   0.43 (0.38-0.50) 0.000   212 (3.38) 430 (7.48)   0.41 (0.35-0.49) <0.001   0.848 
Definite stent thrombosis 57 (0.80) 84 (1.36)   0.58 (0.40-0.83) 0.003   24 (0.38) 50 (0.87)   0.37 (0.22-0.61) <0.001   0.201 
                            
 Effect of drug-eluting stents (DES) vs. bare-metal stents (BMS) in patients undergoing percutaneous coronary intervention in the LAD/LM vs. no-LAD/LM territory. Outcomes are 
displayed after the exclusion of early-generation drug-eluting stents (Cypher SES and Taxus PES). Data are shown at maximum, 5-year, and 1-year follow-up. HR: hazard ratio. MI: 









Figure S1. Kaplan-Meier curves Kaplan-Meier curves for the primary and secondary outcomes 
in patients undergoing percutaneous coronary intervention in the LAD/LM (red line) vs. no-
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Figure S2. Two-stage random effects meta-analysis comparing DES vs. BMS in patients 
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Figure S3. Two-stage random effects meta-analysis comparing DES vs. BMS in patients 
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